Takeaways Hims & Hers is using generic semaglutide to anchor its Canadian weight‑loss and metabolic program, giving it a priced‑in, recurring revenue product at about CAD 149/month that...
Takeaways Hemgenix has moved from theory to practice in Canada, with the first patient now treated outside a trial and public funding in place in Ontario and British Columbia. Market‑wise, this...
Takeaways Optimi is using its Nasdaq uplist and 1‑for‑30 share consolidation to raise roughly 15 million US dollars at scale, then plow the cash into making and selling ...
Takeaways Phoenix and Raven are turning Canada’s new generic semaglutide approvals into immediate, retail-like access, which will likely accelerate GLP‑1 uptake beyond traditional bric...
Takeaways Blenrep’s pCPA negotiations are an important step toward broader Canadian access to a new multiple myeloma option, especially because the drug is being positio...
Takeaways Ontario’s first dedicated AI safety division could make PSHSA a more important player in workplace compliance by turning its expertise into scalable digital tools. The ...
Takeaways Orimed’s expanded PrLuxa‑D line should make vitamin D supplementation more flexible in Canada by covering a much wider dose range, which helps physicians match treatment to defici...
The COVID-19 pandemic exposed critical vulnerabilities in global biopharma supply chains, disrupting the flow of raw materials, APIs, and finished therapies at an unprecedented scale. What was once op...
Takeaways Thyconvi gives BioSyent a differentiated way into Canadian endocrinology by offering the first liquid levothyroxine, so it can compete on convenience and dosing flexibility r...
Takeaways Novartis is using this initiative to deepen its positioning as a “health equity partner” to government and community groups in Canada, with a fresher focus on women and gender‑diverse ...